Werewolf prepares to bare its teeth in 1st trial for targeted cytokine tumor fighters with new round of investor cash
Boston area biotech Werewolf Therapeutics launched in late 2019 with the goal of chasing novel immune system modulators to eradicate solid tumors. Just over a year after hitting the ground running, Werewolf has three candidates in development and has its eyes set on the clinic with a new round of funding.
Werewolf on Thursday unveiled a $72 million Series B round to move its immunotherapies, which target the microenvironments of solid cancer tumors, to Phase I clinical proof-of-concept studies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.